OnKure Therapeutics (OKUR) Cash from Investing Activities (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Cash from Investing Activities came in at -$5000.0 in Q1 2026, up 72.22% YoY from -$2903.2 in Q1 2025, and up 44.44% on a QoQ basis from -$9000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Cash from Investing Activities (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Cash from Investing Activities data on file, last reported at -$5000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 72.22% year-over-year to -$5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33000.0 (down 100.21% YoY) and the FY2025 annual result came in at -$46000.0, down 100.29% from the prior year.
- Cash from Investing Activities rose to -$5000.0 in Q1 2026, from -$9000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $29.0 million in Q4 2023 to a low of -$69.0 million in Q2 2023.
- A 5-year average of -$2.5 million and a median of -$9000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 21808.0% in 2022, down 907.65% in 2022.
- Tracing OKUR's Cash from Investing Activities over 5 years: stood at -$26.9 million in 2022, then jumped by 207.77% to $29.0 million in 2023, then slumped by 45.15% to $15.9 million in 2024, then plunged by 100.06% to -$9000.0 in 2025, then surged by 44.44% to -$5000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$5000.0 (Q1 2026), -$9000.0 (Q4 2025), and -$6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | -9.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.87 Mn |
| Jun 30, 2026 | -9.87 Mn |
| Mar 31, 2026 | -5,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | 15.91 Mn |
| Dec 31, 2024 | 15.91 Mn |
| Sep 30, 2024 | -18,000.00 |
| Sep 30, 2024 | -18,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -9,000.00 |
| Mar 31, 2024 | -9,000.00 |